Clinical Trials Logo

Human Papillomavirus-16 Positive clinical trials

View clinical trials related to Human Papillomavirus-16 Positive.

Filter by:
  • None
  • Page 1

NCT ID: NCT03603808 Active, not recruiting - Clinical trials for Anal Intraepithelial Neoplasia

VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions

Start date: September 21, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies the use of human papillomavirus (HPV) deoxyribonucleic acid (DNA) plasmids therapeutic vaccine VGX-3100 (VGX-3100) and electroporation in treating patients with human immunodeficiency virus (HIV)-positive high-grade anal lesions. Vaccines made from DNA may help the body build an effective immune response to kill tumor cells. Electroporation helps pores in your body's cells take in the drug to strengthen your immune system's response. Giving VGX-3100 and electroporation together may work better in treating patients with high-grade anal lesions.

NCT ID: NCT03439085 Active, not recruiting - Clinical trials for Recurrent Cervical Carcinoma

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

Start date: November 14, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well deoxyribonucleic acid (DNA) plasmid-encoding interleukin-12/human papillomavirus (HPV) DNA plasmids therapeutic vaccine INO-3112 and durvalumab work in treating patients with human papillomavirus associated cancers that have come back or spread to other places in the body. Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving DNA plasmid-encoding interleukin-12/HPV DNA plasmids therapeutic vaccine INO-3112 and durvalumab may work better in treating patients with human papillomavirus associated cancers.